Positron Emission Tomography of Amyloid in Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00205621
Recruitment Status : Suspended
First Posted : September 20, 2005
Last Update Posted : September 8, 2006
Information provided by:
VU University Medical Center

Brief Summary:
In this study in-vivo quantification of amyloid load will be performed in patients with AD, MCI and normal controls with Positron Emission Tomography. For this the PET tracers [11C]PIB and [18F]FDDNP will be compared.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Device: Positron Emission Tomography Phase 1

Detailed Description:
Alzheimer’s disease (AD) is a fatal neurodegenerative disorder characterized by progressive impairment in daily life, cognitive deterioration, and a variety of neuropsychiatric and behavioural symptoms. The diagnosis of AD is based on clinical criteria, but these have low sensitivity and specificity for AD in the early stages of the disease. Therefore, there is a great need for a method to identify the pathological process of AD at an earlier, preclinical stage. In-vivo imaging and quantification of pathological beta-amyloid (Aß) accumulation may provide such a method as the production and accumulation of Aß is thought to be central to the pathogenesis of AD. The view is widely held that Aß may be present in the brain at sublethal concentrations for extended periods before the overt manifestation of AD. Therefore, early, in-vivo detection of pathological Aß accumulation is warranted and may identify subjects at risk for AD. Neuroimaging with Positron Emission Tomography (PET) permits in-vivo imaging and quantification of cerebral amyloid load, which is a novel application of PET. Recently, several PET tracers ([18F]FDDNP and [11C]PIB) have been developed for this purpose and the first clinical studies in patients with AD are encouraging. For both tracers, many methodological issues still need to be resolved and the clinical value of in-vivo amyloid imaging remains to be established. The most important objectives of this project are twofold: to provide an independent and unbiased evaluation of the value of in-vivo amyloid imaging in the (early) diagnosis of AD and to optimize methods for quantification of the in-vivo cerebral amyloid load. To investigate the value in the early diagnosis, identification of subjects at risk for AD is essential. Patients with amnestic mild cognitive impairment (MCI), i.e patients suffering only from memory problems but without the other symptoms of AD, are recruited for this purpose. MCI is a disease state considered to be a transitional state between normal aging and dementia. It is generally accepted that the ability to identify the presence of Alzheimer type pathology in the MCI stage will benefit disease management. Twenty patients with amnestic MCI, 15 patients with AD and 15 age and sex matched healthy controls will be included in this study. Only consecutive new patients fulfilling criteria of amnestic MCI will be included. Patients with MCI will remain under clinical observation during two years after participation in order to monitor conversion to clinical dementia. All subjects will receive [11C]PIB and [18F]FDDNP PET scans on a single day. In addition, patients will receive a [18F]FDG PET scan. Furthermore, an MRI scan, a neuropsychological evaluation and CSF analysis for diagnostic purposes will be performed in all subjects.

Study Type : Interventional  (Clinical Trial)
Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Positron Emission Tomography of Cerebral Amyloid Load as a Potential Diagnostic Marker for Pre-Symptomatic Alzheimer’s Disease.
Study Start Date : October 2005
Study Completion Date : December 2009

Primary Outcome Measures :
  1. quantification of amyloid binding

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Clinical diagnosis of probable Alzheimer’s disease (NINCDS-ADRDA criteria)
  • Clinical diagnosis of MCI according to the criteria of Petersen
  • Age between 60 and 80 years
  • Written informed consent of each subject.
  • Hb must be >8 mmol \ litre at the time of the screening for males and >7 mmol\litre for females.
  • Weight >50 kg
  • All subjects have to be “wilsbekwaam”

Exclusion Criteria:

  • Any clinical significant abnormality of any clinical laboratory test
  • Any subject who has received any investigational medication within 30 days prior to the start of this study, or who is scheduled to receive an investigational drug.
  • Major psychiatric or neurological disorder other than AD
  • History of AD in first degree relatives (controls only)
  • History of alcohol and/or drug abuse (DSM-IV criteria)
  • Any sign of cardiovascular disease including ECG
  • Claustrophobia
  • Mini Mental State Score below 20
  • Use of non-steroid anti-inflammatory drugs
  • Abnormalities on MRI other than white matter changes or an incidental small lacunar lesion.
  • Blood donation within 3 months before the scan day
  • Metal objects in or around the body (braces, pacemaker, metal fragments)
  • Use of antithrombotics and ASA
  • Fall ≤ 6 months or any relevant gait disorder
  • Need for elective surgery ≤ 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00205621

VU University Medical Center
Amsterdam, Netherlands, 1081 HV
Sponsors and Collaborators
VU University Medical Center
Principal Investigator: Bart van Berckel, MD; PhD VU University Medical Center Identifier: NCT00205621     History of Changes
Other Study ID Numbers: 2005/90
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: September 8, 2006
Last Verified: August 2005

Keywords provided by VU University Medical Center:
Alzheimer's disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders